Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization-Reference-Cited by-同舟云学术

Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization

Published:2022-08-29 Issue:8 Volume:5 Page:e2228997
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Anderson Timothy S.¹²,O’Donoghue Ashley²,Mechanic Oren³⁴,Dechen Tenzin²,Stevens Jennifer²⁵

Affiliation:

1. Division of General Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

2. Center for Healthcare Delivery Science, Beth Israel Deaconess Medical Center, Boston, Massachusetts

3. Harvard Medical Faculty Physicians at Beth Israel Deaconess Medical Center, Boston, Massachusetts

4. Department of Emergency Medicine, Mount Sinai Medical Center, Miami Beach, Florida

5. Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Deaconess Medical Center, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2795735/anderson_2022_ld_220184_1660934994.72719.pdf

Reference5 articles.

1. US Food and Drug Administration. Coronavirus (COVID-19) update: FDA limits use of certain monoclonal antibodies to treat COVID-19 due to the Omicron variant. January 24, 2022. Accessed March 12, 2022. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-limits-use-certain-monoclonal-antibodies-treat-covid-19-due-omicron

2. Levin? J, Wingrove? J. DeSantis touts Covid treatments after FDA says they don’t work. Bloomberg. January 25, 2022. Accessed March 12, 2022. https://www.bloomberg.com/news/articles/2022-01-25/desantis-touts-covid-treatments-after-fda-says-they-don-t-work

3. US Department of Health and Human Services. COVID-19 reported patient impact and hospital capacity by state timeseries. 2022. Accessed March 12, 2022. https://healthdata.gov/Hospital/COVID-19-Reported-Patient-Impact-and-Hospital-Capa/g62h-syeh

4. Centers for Disease Control and Prevention. Trends in number of COVID-19 cases and deaths in the US reported to CDC, by state/territory. 2022. Accessed March 12, 2022. https://covid.cdc.gov/covid-data-tracker/#trends_dailycases

5. Centers for Medicare and Medicaid Services. COVID-19 vaccines and monoclonal antibodies. Accessed March 12, 2022. https://www.cms.gov/medicare/medicare-part-b-drug-average-sales-price/covid-19-vaccines-and-monoclonal-antibodies

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Single Monoclonal Antibodies Should Not Be Used for Coronavirus Disease 2019 Therapy: A Call for Antiviral Stewardship;Clinical Infectious Diseases;2024-08-08

2. Considerations for the development of monoclonal antibodies to address new viral variants in COVID-19;Expert Opinion on Biological Therapy;2024-08-02

3. The efficacy of antivirals, corticosteroids, and monoclonal antibodies as acute COVID-19 treatments in reducing the incidence of long COVID: a systematic review and meta-analysis;Clinical Microbiology and Infection;2024-07

4. COVID-19 therapeutics;Clinical Microbiology Reviews;2024-06-13

5. Design of targeted antiviral polypeptides specific to SARS-CoV-2. Challenges and prospects;Russian Chemical Reviews;2024-06